If 75% of all women are considered to be suffered from vulvovaginal candidiasis at least one episode during their lifetime, it seems to be a great problem to treat this population in terms of cost and time demand. For this reason, it is important to shorten the time to treat this disease. From this standpoint, this prospective study was planned to search the efficacy of single-dose oral and local therapy. Ninety-two patients with clinically and microbiologically proven candidal vaginitis , in reproductive age, were included in the study. Thirty-seven nonpregnant women were given oral single-dose fluconazole (150 mg/1day), and 40 women had intravaginal single-dose isoconazole (300 mg/ 1 day). Twenty-five out of 40 were pregnant in 2nd or 3rd trimester. Fifteen patients served as controls and had oral ketoconazol (400 mg/day) for 5 days. Patients were evaluated 10 days later and vaginal culture was repeated. Symptomatic and mycologic cure was attained by 91.8% of the fluconazole group, 82.5% of isoconazole group, and 86.6% of ketoconazole group. A statistically significant difference did not exist for any of these measures (p>0.05, Fisher’s exact test). As a conclusion, long-term therapy is not superior to single-dose therapy. Therefore, single-dose therapy seems to be beneficial in terms of time demand, cost and adverse effects. [Journal of Turgut Ozal Medical Center 1996;3(2):93-96]
Key Words: Vulvovaginal candidiasis, fluconazole, isoconazole, ketokonazole
|
